No image
Imatinib 80 mg/mL Oral Sol.
Product Overview
| Generic Name | Imatinib 80 mg/mL Oral Sol. |
| Brand Name(s) | Gleevec |
| Category | Antineoplastic / Cancer |
| Form | Oral Sol 80 mg/mL of 240 mL |
| Strength | 80 mg/mL |
| Therapeutic Class | Tyrosine-kinase inhibitor |
| ATC Code | L01EA01 |
Manufacturing & Regulatory
| Manufacturer | Novartis |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Type II/III |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | 10 units |
| Shelf Life | 24 months |
| Storage | 20–25 °C |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 to 10 Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Yes |
| SDS-Safety Data Sheet (PDF) | Upon Request |
| CTD Summary (PDF) | CTD from originator; generic use abbreviated formats |
Special Notes
This is the Oral Solution presentation of 80 mg/mL of 240mL Oral Sol.
Use and Indications for Imatinib: Imatinib is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia (CML), Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), gastrointestinal stromal tumors (GIST), and other malignancies driven by BCR-ABL, KIT, or PDGFR mutations. It works by inhibiting abnormal tyrosine kinase signaling involved in cancer cell proliferation.